Skip to main content
Erschienen in: Critical Care 3/2007

01.06.2007 | Commentary

Attributable mortality of Acinetobacter baumannii: no longer a controversial issue

verfasst von: Matthew E Falagas, Petros I Rafailidis

Erschienen in: Critical Care | Ausgabe 3/2007

Einloggen, um Zugang zu erhalten

Abstract

There has been controversy regarding the mortality directly attributed to Acinetobacter baumannii infections. Data from six case–control studies have been recently added to the literature regarding the attributable mortality of A. baumannii infections during the past months. The information from these studies, added to the previous knowledge on this issue, provides evidence that A. baumannii infections are indeed associated with increased mortality. In addition, there is relevant evidence from studies examining the effect of inappropriate treatment on mortality; specifically, inappropriate treatment of A. baumannii infections has been associated with excess mortality. We believe that the accumulated data suggest that attributable mortality due to A. baumannii infections should no longer be a controversial issue. The efforts of the scientific community interested in this pathogen should therefore be directed to the development and introduction of new antibiotics effective against multidrug-resistant and pandrug-resistant A. baumannii as well as the implementation of infection control measures that may help us in the control of the increasing problem of A. baumannii infections.
Literatur
1.
Zurück zum Zitat Fournier PE, Richet H: The epidemiology and control of Acinetobacter baumannii in health care facilities. Clin Infect Dis 2006, 42: 692-699. 10.1086/500202CrossRefPubMed Fournier PE, Richet H: The epidemiology and control of Acinetobacter baumannii in health care facilities. Clin Infect Dis 2006, 42: 692-699. 10.1086/500202CrossRefPubMed
2.
Zurück zum Zitat Harbarth S, Nobre V, Pittet D: Does antibiotic selection impact patient outcome? Clin Infect Dis 2007, 44: 87-93. 10.1086/510075CrossRefPubMed Harbarth S, Nobre V, Pittet D: Does antibiotic selection impact patient outcome? Clin Infect Dis 2007, 44: 87-93. 10.1086/510075CrossRefPubMed
3.
Zurück zum Zitat Falagas ME, Kopterides P, Siempos II: Attributable mortality of Acinetobacter baumannii infection among critically ill patients [letter]. Clin Infect Dis 2006, 43: 389. author reply 389–390 10.1086/505599CrossRefPubMed Falagas ME, Kopterides P, Siempos II: Attributable mortality of Acinetobacter baumannii infection among critically ill patients [letter]. Clin Infect Dis 2006, 43: 389. author reply 389–390 10.1086/505599CrossRefPubMed
4.
Zurück zum Zitat Falagas ME, Bliziotis IA, Siempos II: Attributable mortality of Acinetobacter baumannii infections in critically ill patients: a systematic review of matched cohort and case–control studies. Crit Care 2006, 10: R48. 10.1186/cc4869PubMedCentralCrossRefPubMed Falagas ME, Bliziotis IA, Siempos II: Attributable mortality of Acinetobacter baumannii infections in critically ill patients: a systematic review of matched cohort and case–control studies. Crit Care 2006, 10: R48. 10.1186/cc4869PubMedCentralCrossRefPubMed
5.
Zurück zum Zitat Falagas ME, Kasiakou SK, Rafailidis PI, Zouglakis G, Morfou P: Comparison of mortality of patients with Acinetobacter baumannii bacteraemia receiving appropriate and inappropriate empirical therapy. J Antimicrob Chemother 2006, 57: 1251-1254. 10.1093/jac/dkl130CrossRefPubMed Falagas ME, Kasiakou SK, Rafailidis PI, Zouglakis G, Morfou P: Comparison of mortality of patients with Acinetobacter baumannii bacteraemia receiving appropriate and inappropriate empirical therapy. J Antimicrob Chemother 2006, 57: 1251-1254. 10.1093/jac/dkl130CrossRefPubMed
6.
Zurück zum Zitat Sunenshine RH, Wright MO, Maragakis LL, Harris AD, Song X, Hebden J, Cosgrove SE, Anderson A, Carnell J, Jernigan DB, et al.: Multidrug-resistant Acinetobacter infection mortality rate and length of hospitalization. Emerg Infect Dis 2007, 13: 97-103.PubMedCentralCrossRefPubMed Sunenshine RH, Wright MO, Maragakis LL, Harris AD, Song X, Hebden J, Cosgrove SE, Anderson A, Carnell J, Jernigan DB, et al.: Multidrug-resistant Acinetobacter infection mortality rate and length of hospitalization. Emerg Infect Dis 2007, 13: 97-103.PubMedCentralCrossRefPubMed
7.
Zurück zum Zitat Grupper M, Sprecher H, Mashiach T, Finkelstein R: Attributable mortality of nosocomial acinetobacter bacteremia. Infect Control Hosp Epidemiol 2007, 28: 293-298. 10.1086/512629CrossRefPubMed Grupper M, Sprecher H, Mashiach T, Finkelstein R: Attributable mortality of nosocomial acinetobacter bacteremia. Infect Control Hosp Epidemiol 2007, 28: 293-298. 10.1086/512629CrossRefPubMed
8.
Zurück zum Zitat Playford EG, Craig JC, Iredell JR: Carbapenem-resistant Acinetobacter baumannii in intensive care unit patients: risk factors for acquisition, infection and their consequences. J Hosp Infect 2007, 65: 204-211. 10.1016/j.jhin.2006.11.010CrossRefPubMed Playford EG, Craig JC, Iredell JR: Carbapenem-resistant Acinetobacter baumannii in intensive care unit patients: risk factors for acquisition, infection and their consequences. J Hosp Infect 2007, 65: 204-211. 10.1016/j.jhin.2006.11.010CrossRefPubMed
9.
Zurück zum Zitat Kwon KT, Oh WS, Song JH, Chang HH, Jung SI, Kim SW, Ryu SY, Heo ST, Jung DS, Rhee JY, et al.: Impact of imipenem resistance on mortality in patients with Acinetobacter bacteraemia . J Antimicrob Chemother 2007, 59: 525-530. 10.1093/jac/dkl499CrossRefPubMed Kwon KT, Oh WS, Song JH, Chang HH, Jung SI, Kim SW, Ryu SY, Heo ST, Jung DS, Rhee JY, et al.: Impact of imipenem resistance on mortality in patients with Acinetobacter bacteraemia . J Antimicrob Chemother 2007, 59: 525-530. 10.1093/jac/dkl499CrossRefPubMed
10.
Zurück zum Zitat Robenshtok E, Paul M, Leibovici L, Fraser A, Pitlik S, Ostfeld I, Samra Z, Perez S, Lev B, Weinberger M: The significance of Acinetobacter baumannii bacteraemia compared with Klebsiella pneumoniae bacteraemia: risk factors and outcomes. J Hosp Infect 2006, 64: 282-287. 10.1016/j.jhin.2006.06.025CrossRefPubMed Robenshtok E, Paul M, Leibovici L, Fraser A, Pitlik S, Ostfeld I, Samra Z, Perez S, Lev B, Weinberger M: The significance of Acinetobacter baumannii bacteraemia compared with Klebsiella pneumoniae bacteraemia: risk factors and outcomes. J Hosp Infect 2006, 64: 282-287. 10.1016/j.jhin.2006.06.025CrossRefPubMed
11.
Zurück zum Zitat Gkrania-Klotsas E, Hershow RC: Colonization or infection with multidrug-resistant Acinetobacter baumannii may be an independent risk factor for increased mortality. Clin Infect Dis 2006, 43: 1224-1225. 10.1086/508360CrossRefPubMed Gkrania-Klotsas E, Hershow RC: Colonization or infection with multidrug-resistant Acinetobacter baumannii may be an independent risk factor for increased mortality. Clin Infect Dis 2006, 43: 1224-1225. 10.1086/508360CrossRefPubMed
12.
13.
Zurück zum Zitat Zaragoza R, Artero A, Camarena JJ, Sancho S, Gonzalez R, Nogueira JM: The influence of inadequate empirical antimicrobial treatment on patients with bloodstream infections in an intensive care unit. Clin Microbiol Infect 2003, 9: 412-418. 10.1046/j.1469-0691.2003.00656.xCrossRefPubMed Zaragoza R, Artero A, Camarena JJ, Sancho S, Gonzalez R, Nogueira JM: The influence of inadequate empirical antimicrobial treatment on patients with bloodstream infections in an intensive care unit. Clin Microbiol Infect 2003, 9: 412-418. 10.1046/j.1469-0691.2003.00656.xCrossRefPubMed
14.
Zurück zum Zitat Lee SC, Hua CC, Yu TJ, Shieh WB, See LC: Risk factors of mortality for nosocomial pneumonia: importance of initial anti-microbial therapy. Int J Clin Pract 2005, 59: 39-45. 10.1111/j.1742-1241.2005.00281.xCrossRefPubMed Lee SC, Hua CC, Yu TJ, Shieh WB, See LC: Risk factors of mortality for nosocomial pneumonia: importance of initial anti-microbial therapy. Int J Clin Pract 2005, 59: 39-45. 10.1111/j.1742-1241.2005.00281.xCrossRefPubMed
Metadaten
Titel
Attributable mortality of Acinetobacter baumannii: no longer a controversial issue
verfasst von
Matthew E Falagas
Petros I Rafailidis
Publikationsdatum
01.06.2007
Verlag
BioMed Central
Erschienen in
Critical Care / Ausgabe 3/2007
Elektronische ISSN: 1364-8535
DOI
https://doi.org/10.1186/cc5911

Weitere Artikel der Ausgabe 3/2007

Critical Care 3/2007 Zur Ausgabe

Delir bei kritisch Kranken – Antipsychotika versus Placebo

16.05.2024 Delir Nachrichten

Um die Langzeitfolgen eines Delirs bei kritisch Kranken zu mildern, wird vielerorts auf eine Akuttherapie mit Antipsychotika gesetzt. Eine US-amerikanische Forschungsgruppe äußert jetzt erhebliche Vorbehalte gegen dieses Vorgehen. Denn es gibt neue Daten zum Langzeiteffekt von Haloperidol bzw. Ziprasidon versus Placebo.

Eingreifen von Umstehenden rettet vor Erstickungstod

15.05.2024 Fremdkörperaspiration Nachrichten

Wer sich an einem Essensrest verschluckt und um Luft ringt, benötigt vor allem rasche Hilfe. Dass Umstehende nur in jedem zweiten Erstickungsnotfall bereit waren, diese zu leisten, ist das ernüchternde Ergebnis einer Beobachtungsstudie aus Japan. Doch es gibt auch eine gute Nachricht.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

07.05.2024 Klinik aktuell Nachrichten

Extreme Arbeitsverdichtung und kaum Supervision: Dr. Andrea Martini, Sprecherin des Bündnisses Junge Ärztinnen und Ärzte (BJÄ) über den Frust des ärztlichen Nachwuchses und die Vorteile des Rucksack-Modells.

Update AINS

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.